Susquehanna International Group
APLS

Susquehanna International Group’s Apellis Pharmaceuticals APLS Stock Holding History

Susquehanna International Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3M Sell
280,600
-376,600
-57% -$8.12M ﹤0.01% 2931
2025
Q4 		$16.5M Buy
657,200
+188,200
+40% +$4.42M ﹤0.01% 2420
2025
Q3 		$10.6M Sell
469,000
-47,800
-9% -$1.11M ﹤0.01% 2967
2025
Q2 		$8.95M Buy
516,800
+193,300
+60% +$3.58M ﹤0.01% 2989
2025
Q1 		$7.07M Sell
323,500
-535,700
-62% -$14.8M ﹤0.01% 3020
2024
Q4 		$27.4M Buy
859,200
+71,700
+9% +$2.16M ﹤0.01% 1607
2024
Q3 		$22.7M Sell
787,500
-241,300
-23% -$8.94M ﹤0.01% 1705
2024
Q2 		$39.5M Buy
1,028,800
+707,000
+220% +$32M 0.01% 1144
2024
Q1 		$18.9M Sell
321,800
-623,900
-66% -$39.8M ﹤0.01% 1845
2023
Q4 		$56.6M Sell
945,700
-74,000
-7% -$3.75M 0.01% 969
2023
Q3 		$38.8M Buy
1,019,700
+864,700
+558% +$38M 0.01% 1194
2023
Q2 		$14.1M Sell
155,000
-203,200
-57% -$17.5M ﹤0.01% 2090
2023
Q1 		$23.6M Buy
358,200
+170,400
+91% +$9.83M 0.01% 1542
2022
Q4 		$9.71M Buy
187,800
+24,500
+15% +$1.3M ﹤0.01% 2311
2022
Q3 		$11.2M Buy
163,300
+132,300
+427% +$7.83M ﹤0.01% 2021
2022
Q2 		$1.4M Sell
31,000
-148,500
-83% -$6.77M ﹤0.01% 5711
2022
Q1 		$9.12M Buy
179,500
+78,200
+77% +$3.45M ﹤0.01% 2672
2021
Q4 		$4.79M Sell
101,300
-425,500
-81% -$16.8M ﹤0.01% 3814
2021
Q3 		$17.4M Buy
526,800
+69,100
+15% +$3.88M ﹤0.01% 2139
2021
Q2 		$28.9M Buy
457,700
+333,200
+268% +$17.2M ﹤0.01% 1639
2021
Q1 		$5.34M Buy
124,500
+24,700
+25% +$1.17M ﹤0.01% 3787
2020
Q4 		$5.71M Buy
99,800
+23,900
+31% +$1.01M ﹤0.01% 3222
2020
Q3 		$2.29M Buy
75,900
+55,600
+274% +$1.66M ﹤0.01% 4364
2020
Q2 		$663K Sell
20,300
-22,300
-52% -$716K ﹤0.01% 6763
2020
Q1 		$1.14M Sell
42,600
-113,200
-73% -$4.02M ﹤0.01% 5094
2019
Q4 		$4.77M Buy
155,800
+82,100
+111% +$2.27M ﹤0.01% 3029
2019
Q3 		$1.77M Buy
+73,700
New +$2.03M ﹤0.01% 4452

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna International Group's APLS Position: Q1 2026 in Review

Susquehanna International Group reduced its Apellis Pharmaceuticals (APLS) stake by 36% in Q1 2026, selling an estimated $4.18M and leaving 340,086 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.

Susquehanna International Group first reported a position in APLS in Q2 2019 and has held it in 28 quarters since. The position peaked at $28.8M in Q2 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Susquehanna International Group held 340,086 shares of Apellis Pharmaceuticals worth $13.7M as of Q1 2026.
  • Susquehanna International Group sold 193,823 Apellis Pharmaceuticals shares in Q1 2026, an estimated $4.18M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2675 holding.
  • Susquehanna International Group first reported a position in Apellis Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Susquehanna International Group's Apellis Pharmaceuticals position peaked at $28.8M in Q2 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.